FGF19 and metabolic dysfunction-associated steatohepatitis: However, treatment with only FGF19 seems not sufficient for MASH treatment because a clinical trial to test the effectiveness of modified FGF19 in MASH treatment did not provide promising results,21 suggesting that additional understanding of MASH pathogenesis and better strategies to treat MASH are needed.